All In Biotech

Drug Trial Radar · NCT06660719

Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care

A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase III Clinical Study to Evaluate Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Requiring Thrombolytic Therapy as Standard of Care

Last checked: Nov 20, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 852 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

852

Planned (sponsor's estimate)

Start

Feb 14, 2025

Primary completion

Mar 30, 2027

Study completion Mar 30, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (otaplimastat) and thrombolytic standard of care in acute ischemic stroke patient. As a standard of care, thrombolytic therapy (for instance, recombinant tissue plasminogen activator) will be administered. When reperfusion is not achieved in spite of thrombolytic therapy, endovascular therapy can be performed.

Conditions

  • Ischemic Stroke

Interventions

  • SP-8203Drug

    SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)

  • PlaceboDrug

    Placebo will be intravenously administered twice daily (intervals of 12 hours)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with modified Rankin Scale (mRS) 0-1Time frame: Day 90

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Dong-A University Hospital

    Busan, South Korea · Recruiting

  • Ulsan University Hospital

    Ulsan, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.